Profitelligence Profitelligence · Filing Ledger Sign up free →

30 filings · most recent first

IBRX 8-K Filings

Immunitybio Reports 700 Yearoveryear Revenue Growth And Expands Global Immunitybio Receives European Commission Authorization For Anktiva With Bcg Immunitybio Inc Amends Convertible Promissory Note Agreement Immunitybio Announces Strong Sales Growth And New Regulatory Approval Immunitybio Receives Accelerated Approval For Anktiva In Saudi Arabia Immunitybio Appoints Bruce Wendel To Board Of Directors Immunitybio Receives Positive Regulatory Update For Anktiva In Europe Immunitybio Reports Strong Q3 2025 Results And Yeartodate Growth Immunitybio Reports 60 Increase In Q2 2025 Revenue With Positive Clinical Trial Immunitybio Approves 2025 Equity Incentive Plan And Announces Annual Meeting Immunitybio Reports Significant Growth In Q1 2025 Revenue And Anktiva Sales Immunitybio Announces Significant Sales Growth And Fda Submissions For Anktiva Immunitybio Appoints New Auditor Immunitybio Reports Increased Sales And Regulatory Updates For Anktiva Immunitybio Announces Completion Of Patient Enrollment In Quilt3032 Study With Immunitybio Announces Thirdquarter 2024 Financial Results And Key Developments Immunitybio Settles Arbitration With Former Employees Acquiring Key Immunitybio Inc Annual Meeting Results Announced Immunitybio Receives Fda Approval For Anktiva To Treat Bcgunresponsive Nmibc Immunitybio Secures 210M In Royalty Financing From Oberland Capital Immunitybio Inc Announces Increase In Authorized Shares And Amendment To Share Immunitybio Settles Shareholder Derivative Actions Immunitybio Announces Securities Purchase Agreement And Q2 2025 Financial Fda Refuses To File Sbla For Bladder Cancer Indication Immunitybio Announces 75 Million Equity Financing Compensation Committee Approves 2024 Bonuses And 2025 Compensation Arrangements John Owen Brennan Resigns From Immunitybio Inc Board Of Directors Immunitybio Announces Pricing Of Public Offering And Debt Restructuring Immunitybio Announces Public Offering And Debt Restructuring Immunitybio Approves 2023 Executive Bonuses And Amends Code Of Ethics
IBRX full research: price, insiders, financials →